10-Q: Amarin Reports Increased Net Loss Amid US Generic Pressure, Pivots to European Licensing with Recordati Deal

Amarin Corporation plc reported a significant increase in net loss for the first half of 2025, driven by restructuring costs from a new European licensing agreement with Recordati and continued challenges in the U.S. market due to generic competition.

Summary

• Net loss for the six months ended June 30, 2025, increased to $29.8 million, compared to a net loss of $8.4 million for the same period in 2024.
• Total revenue for the six months ended June 30, 2025, decreased by 7% to $114.8 million from $124.0 million in 2024.
• U.S. product revenue declined by 21% to $72.2 million, primarily due to generic competition and the loss of a large national pharmacy benefit manager.
• Amarin's share of the U.S. icosapent ethyl market decreased to approximately 42% in the first half of 2025, down from 57% in the first half of 2024.
• Branded VASCEPA prescriptions in the U.S. decreased by 26% for the six months ended June 30, 2025, compared to the same period in 2024.
• European product revenue increased to $12.0 million from $5.4 million, while licensing and royalty revenue rose by 27% to $27.1 million, boosted by a $25.0 million upfront payment from the Recordati EU Licensing Agreement.
• The company initiated a global restructuring plan, incurring $22.8 million in expenses during the period, with anticipated annual cost savings of approximately $70.0 million, mainly from eliminating European commercial roles.
• Gross margin on product sales improved to 55% from 52% due to a change in customer mix.
• Cash and cash equivalents increased to $147.9 million as of June 30, 2025, from $121.0 million at December 31, 2024.
• A share repurchase program of up to $50.0 million was approved in Q2 2024 but has not yet been utilized.
• Accumulated deficit reached $1.7 billion as of June 30, 2025.

Sentiment

Score: 4

Explanation: The company faces significant headwinds from generic competition in its primary U.S. market, leading to substantial revenue decline and increased net losses. While strategic moves like the Recordati deal and restructuring aim for long-term cost savings and international growth, the immediate financial impact is negative. The stock faces ongoing legal uncertainties and the success of the new international strategy is yet to be fully realized. Given the mixed signals—deteriorating U.S. performance offset by strategic international moves and cost-cutting—the overall sentiment is moderately negative.

Positives

• Net cash provided by operating activities improved significantly to $4.1 million for the six months ended June 30, 2025, compared to net cash used of $15.4 million in the prior year.
• Gross margin on product sales increased to 55% for the six months ended June 30, 2025, up from 52% in the same period of 2024, driven by a favorable change in customer mix.
• Licensing and royalty revenue increased by 27% to $27.1 million, primarily due to a $25.0 million upfront payment from the new Recordati EU Licensing Agreement.
• The global restructuring plan is expected to generate approximately $70.0 million in annual cost savings, primarily from the elimination of European commercial roles.
• European product revenue increased to $12.0 million for the six months ended June 30, 2025, from $5.4 million in the prior year.
• Regained compliance with Nasdaq's minimum bid price requirement on April 29, 2025, following the ADS Ratio Change.
• Over 55 clinical treatment guidelines globally recognize the use of icosapent ethyl (IPE) for cardiovascular risk reduction.

Negatives

• Net loss significantly increased to $29.8 million for the six months ended June 30, 2025, compared to $8.4 million for the same period in 2024.
• Total revenue decreased by 7% to $114.8 million for the six months ended June 30, 2025.
• U.S. product revenue declined by 21% to $72.2 million, primarily due to generic competition and the loss of a large national pharmacy benefit manager.
• Amarin's share of the U.S. icosapent ethyl market decreased to approximately 42% in the first half of 2025, down from 57% in the first half of 2024.
• Branded VASCEPA prescriptions in the U.S. decreased by 26% for the six months ended June 30, 2025, compared to the same period in 2024.
• Incurred $22.8 million in restructuring expense during the six months ended June 30, 2025, related to the global restructuring plan.
• Accumulated deficit reached $1.7 billion as of June 30, 2025.
• Interest income, net, decreased by 17% to $5.5 million for the six months ended June 30, 2025, due to lower interest rates.

Risks

• Dependence on collaboration partners (e.g., Recordati) for commercialization in key markets, with risks including insufficient effort, mismanagement of supply chain, unfavorable pricing, changes in key personnel, or business combinations.
• Inability to successfully market and sell VASCEPA in the U.S. due to generic competition, potentially impacting revenues and profitability.
• Failure of the global restructuring plan to mitigate business risks or achieve anticipated cost savings.
• Potential delisting from Nasdaq if the company is unable to maintain compliance with listing requirements, which would adversely impact liquidity and share price.
• Adverse effects from tariffs, trade sanctions, or similar government actions on business, financial condition, results of operations, and cash flows.
• Uncertainty regarding the outcome of ongoing patent infringement litigation against Hikma and other legal proceedings, including a complaint from the former CEO.
• Reliance on third-party manufacturers and suppliers for VASCEPA, with risks of supply interruption or inability to renew agreements on favorable terms.
• Fluctuations in inventory levels at wholesalers and potential inaccuracies in third-party prescription data.
• Difficulty in securing adequate reimbursement for VAZKEPA in European countries, which is requisite for commercial success.

Future Outlook

The company anticipates quarterly net cash outflows to remain variable due to API purchases and the impact of U.S. generic competition and European licensee efforts. It plans to adjust research and development activities based on U.S. generic competition and timing of pricing reimbursements globally. The company believes its current cash and short-term investments are sufficient to fund projected operations, including the share repurchase program, for at least one year from the issuance date of the financial statements.

Management Comments

• We remain confident that the global patient need for VASCEPA is high.
• In 2025, we will continue to focus on getting VASCEPA to as many patients as possible by continuing to support our partners advancing commercialization activities in markets with access and pricing and reimbursement activities to drive access in remaining geographies as well as being the market leader in the U.S.
• We continuously evaluate all of our spending commitments and priorities and we plan to adjust our level of research and development activities based on various factors, including the impact of U.S. generic competition as well as timing of pricing reimbursements throughout the world.

Industry Context

The pharmaceutical industry, particularly in cardiovascular health, faces significant challenges from generic competition and complex reimbursement landscapes. Amarin's strategy to shift from direct commercialization in Europe to a licensing model with Recordati reflects a common industry trend to optimize costs and leverage partner expertise in specific regions, especially in the face of patent expirations and market pressures. The continued decline in U.S. branded prescription share highlights the intense competitive environment from generic versions of icosapent ethyl. The emphasis on international partnerships and securing reimbursement in new markets is crucial for growth given the mature and competitive U.S. market.

Comparison to Industry Standards

• The decline in U.S. branded VASCEPA prescriptions and market share is consistent with the typical impact of generic drug entry on branded pharmaceutical products, where generic versions often capture a significant portion of the market due to lower pricing.
• The strategy of licensing commercialization rights in Europe to a partner like Recordati is a common approach for pharmaceutical companies to reduce direct operational costs and leverage established regional sales and distribution networks, especially when facing market access complexities and the need for specialized reimbursement expertise.
• The company's gross margin improvement, despite revenue decline, suggests effective cost management or a shift towards higher-margin sales channels (e.g., international licensing upfront payments), which can be a positive sign of operational efficiency in a challenging market.
• The continued recognition of icosapent ethyl (IPE) in over 55 global clinical guidelines, including recent updates from the National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand and the European Atherosclerosis Society, indicates strong clinical validation and aligns with the industry's focus on evidence-based medicine.

Management Changes

Corporate Governance

Legal Proceedings

• Patent infringement lawsuit against Hikma Pharmaceuticals USA Inc. for induced infringement of patents covering VASCEPA's CV risk reduction use. The Federal Circuit reversed the district court's dismissal, finding a plausible claim. Hikma filed a Petition for a Writ of Certiorari with the Supreme Court on February 14, 2025, while the infringement case continues in district court.
• Complaint filed by former CEO Karim Mikhail against the company and affiliates in New Jersey Superior Court, alleging constructive termination and seeking unspecified damages for breaches of employment agreement, severance plan, and implied covenant of good faith and fair dealing. The case moved to U.S. District Court, and the company filed a new Motion to Dismiss on March 20, 2025.

Stakeholder Impact

• Shareholders: Negative impact from increased net loss and declining U.S. market share. Potential positive impact from long-term cost savings due to restructuring and international growth strategy. Share repurchase program, if utilized, could provide support. Nasdaq compliance regained, reducing delisting risk.
• Employees: Significant impact from the global restructuring plan, leading to the elimination of commercial roles in European operations.
• Customers (U.S.): Continued impact from generic competition, potentially affecting access and pricing for branded VASCEPA.
• Customers (International Partners): Positive impact from new licensing agreements (e.g., Recordati) and regulatory approvals (e.g., China, Australia), expanding market access for VASCEPA/VAZKEPA.
• Suppliers: Ongoing negotiations to align supply arrangements with current and future global demand, potentially leading to changes in purchase commitments.

Next Steps

• Recordati to pursue future VAZKEPA approvals and commercialization in the EU Territory.
• Continue to support partners advancing commercialization activities in international markets with access.
• Continue pricing and reimbursement activities to drive access in remaining geographies.
• Continue efforts to be the market leader in the U.S.
• Continue to publish additional details of the REDUCE-IT study.
• Assess other potential partnership opportunities for VASCEPA in international markets.
• Adjust level of research and development activities based on U.S. generic competition and timing of pricing reimbursements.
• Monitor business and market conditions for potential share repurchases.
• Continue to negotiate with contract suppliers to align supply arrangements with current and future global market demand.
• Former CEO's lawsuit continues to proceed, with the company vigorously defending against claims.
• Hikma patent infringement case continues to proceed within the district court during the pendency of the Supreme Court Petition.

Key Dates

Recommendation

Amarin is in a transitional phase, marked by significant challenges in its core U.S. market due to generic competition and a strategic pivot towards international partnerships and cost optimization. While the Recordati deal and restructuring promise future cost savings and revenue diversification, the immediate financial results show increased losses and declining U.S. market share. The stock faces ongoing legal uncertainties and the success of the new international strategy is yet to be fully realized. Given the mixed signals—deteriorating U.S. performance offset by strategic international moves and cost-cutting—a 'hold' recommendation is appropriate. Investors should monitor the execution of the European strategy, the impact of cost savings, and the trajectory of U.S. market share before considering a stronger position.

Keywords

Amarin, VASCEPA, VAZKEPA, Icosapent Ethyl, Cardiovascular Health, Pharmaceutical, Biotech, Drug Commercialization, Generic Competition, Patent Litigation, Restructuring, European Market, US Market, Financial Results, Nasdaq, Share Repurchase, Corporate Governance